Event to be held via webcast on March 25, 2025 at 4:00 p.m. ET To highlight differentiated drug discovery capabilities with ...
In an exploratory analysis of the TALAPRO-2 results for DDR-mutated patients, the greatest benefit was observed for patients with mutations in BRCA2 (HR, 0.19 [95% CI, 0.10 to 0.38]), no clear rPFS ...
After hours: March 24 at 7:42:57 PM EDT Loading Chart for ACRV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback